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Introduction. In 2012 and 2014, the Therapeutic Goods Administration initiated consultations proposing the 
implementation of a standardised over-the-counter (OTC) medicine label format in Australia. Previous research has 
indicated mixed consumer opinions regarding the proposed label format presented in the 2012 consultation paper 
(Tong et al, 2015). Furthermore, there is limited evidence demonstrating the usability of the proposed formats. 
Aims. (i) To develop and examine the performance of alternative OTC medicine label formats for standardisation 
and; (ii) Explore consumer perspectives on the alternative label formats and required label improvements 
Methods. Findings from an initial qualitative consumer needs analysis were reviewed by an international expert 
panel and used to guide the development of alternative label formats. A total of four alternative OTC label formats 
were developed for the exemplar medicine diclofenac. Individual face-to-face interviews with demographically 
matched cohorts of 10 consumers (total n=50) are currently being conducted to user test each alternative label 
format, as well as a current label for an existing diclofenac product. Each interview consists of: (i) administration of 
a user testing questionnaire to quantitatively measure FRQVXPHUV¶ DELOLW\ WR ILQG DQG XQGHUVWDQG key points of 
information pertaining to diclofenac when using one of the labels and; (ii) a semi-structured interview exploring 
consumer perspectives. 
Results. To date, 21 interviews have been conducted. Overall, the label formats have performed well in supporting 
FRQVXPHUV¶ DELOLW\ WR ERWK ILQG DQG XQGHUVWDQG NH\ SRLQWV RI LQIRUPDWLRQ for diclofenac such as the indication, 
dosage, maximum daily dose, contraindications, treatment duration and further information sources. When shown 
all labels, consumer perspectives on the label formats varied. Factors such as perceived usability, use of colour, 
design, content, and/or content ordering impacted consumer preferences and subsequent rankings of the labels. 
Discussion. Despite the overall satisfactory performance demonstrated by the label formats, consumer perspectives 
are diverse and should be considered when working towards an OTC medicine label format for standardisation. 
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